Brian K. Rutt

Brian K. Rutt

Auto-generated profile, based on publicly available information

Brian K. Rutt

Department of Radiology Stanford University 1201 Welch Road 94305 94305 Stanford Stanford CA CA USA USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in NeuroImage
Verified
Journal Article
Closed access
TTThomas Tourdias
Thomas Tourdias
MSManojkumar Saranathan
Manojkumar Saranathan
ILIves R. Levesque
Ives R. Levesque
JSJason Su
Jason Su
BRBrian K. Rutt
Brian K. Rutt

3 June 2014 in Chemical Science
Verified
Journal Article
Closed access
PDF file
DYDeju Ye
Deju Ye
ASAdam J. Shuhendler
Adam J. Shuhendler
PPPrachi Pandit
Prachi Pandit
KBKimberly D. Brewer
Kimberly D. Brewer
STSui Seng Tee
Sui Seng Tee
JRJianghong Rao
Jianghong Rao
Non-invasive detection of caspase-3/7 activity in vivo has provided invaluable predictive information regarding tumor therapeutic efficacy and anti-tumor drug selection. Although a number of caspase-3/7 targeted fluorescence and positron emission tomography (PET) imaging probes have been developed, there is still a lack of gadolinium (Gd)-based magnetic resonance imaging (MRI) probes that enable high spatial resolution detection of caspase-3/7 activity in vivo. Here we employ a self-assembly approach and develop a caspase-3/7 activatable Gd-based MRI probe for monitoring tumor apoptosis in mice. Upon reduction and caspase-3/7 activation, the caspase-sensitive nano-aggregation MR probe (C-SNAM: 1) undergoes biocompatible intramolecular cyclization and subsequent self-assembly into Gd-nanoparticles (GdNPs). This results in enhanced r1 relaxivity—19.0 (post-activation) vs. 10.2 mM−1 s−1 (pre-activation) at 1 T in solution—and prolonged accumulation in chemotherapy-induced apoptotic cells and tumors that express active caspase-3/7. We demonstrate that C-SNAM reports caspase-3/7 activity by generating a significantly brighter T1-weighted MR signal compared to non-treated tumors following intravenous administration of C-SNAM, providing great potential for high-resolution imaging of tumor apoptosis in vivo.

4 December 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NSNicholas D. Schiff
Nicholas D. Schiff
JGJoseph T. Giacino
Joseph T. Giacino
CBChristopher R Butson
Christopher R Butson
ECEun Young Choi
Eun Young Choi
JBJonathan L. Baker
Jonathan L. Baker
JHJaimie M. Henderson
Jaimie M. Henderson

1 February 2012 in NeuroImage
Verified
Journal Article
Closed access
HKHagen H. Kitzler
Hagen H. Kitzler
JSJason Su
Jason Su
MZMichael Zeineh
Michael Zeineh
CHCynthia Harper-Little
Cynthia Harper-Little
ALAndrew Leung
Andrew Leung
BRBrian K. Rutt
Brian K. Rutt

18 July 2015 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
JRJames A. Rioux
James A. Rioux
ILIves R. Levesque
Ives R. Levesque
BRBrian K. Rutt
Brian K. Rutt

6 August 2020 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
JSJason H. Su
Jason H. Su
ECEun Young Choi
Eun Young Choi
TTThomas Tourdias
Thomas Tourdias
MSManojkumar Saranathan
Manojkumar Saranathan
CHCasey H. Halpern
Casey H. Halpern
BRBrian K. Rutt
Brian K. Rutt
Magnetic resonance‐guided focused ultrasound (MRgFUS) ablation of the ventral intermediate (Vim) thalamic nucleus is an incisionless treatment for essential tremor (ET). The standard initial targeting method uses an approximate, atlas‐based stereotactic approach. We developed a new patient‐specific targeting method to identify an individual's Vim and the optimal MRgFUS target region therein for suppression of tremor. In this retrospective study of 14 ET patients treated with MRgFUS, we investigated the ability of WMnMPRAGE, a highly sensitive and robust sequence for imaging gray matter‐white matter contrast, to identify the Vim, FUS ablation, and a clinically efficacious region within the Vim in individual patients. We found that WMnMPRAGE can directly visualize the Vim in ET patients, segmenting this nucleus using manual or automated segmentation capabilities developed by our group. WMnMPRAGE also delineated the ablation's core and penumbra, and showed that all patients' ablation cores lay primarily within their Vim segmentations. We found no significant correlations between standard ablation features (e.g., ablation volume, Vim‐ablation overlap) and 1‐month post‐treatment clinical outcome. We then defined a group‐based probabilistic target, which was nonlinearly warped to individual brains; this target was located within the Vim for all patients. The overlaps between this target and patient ablation cores correlated significantly with 1‐month clinical outcome (r = −.57, p = .03), in contrast to the standard target (r = −.23, p = .44). We conclude that WMnMPRAGE is a highly sensitive sequence for segmenting Vim and ablation boundaries in individual patients, allowing us to find a novel tremor‐associated center within Vim and potentially improving MRgFUS treatment for ET.